# Study of CM313 in Subject With IgA Nephropathy

> **NCT06830395** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 106 (estimated)

## Conditions studied

- IgA Nephropathy

## Interventions

- **BIOLOGICAL:** CM313
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06830395
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-03
- **Final completion:** 2028-08
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830395, "Study of CM313 in Subject With IgA Nephropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06830395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*